TP53 and acute myeloid leukemia: Although AML with −7 is classified into one ELN adverse-risk group, it should be noted that survival among these clinically poorly performing patients may still differ with a potential survival benefit in IDH2mut patients but at the same time, even poorer outcomes in the presence of TP53 and PTPN11 aberrations.